Passive immunotherapies for the next influenza pandemic

Daniele Focosi; Massimo Franchini; Jonathon W Senefeld; Michael J Joyner; David J Sullivan; Andrew Pekosz; Fabrizio Maggi; Arturo Casadevall

doi:10.1002/rmv.2533

Passive immunotherapies for the next influenza pandemic

Rev Med Virol. 2024 May;34(3):e2533. doi: 10.1002/rmv.2533.

Authors

Daniele Focosi¹, Massimo Franchini², Jonathon W Senefeld^{3

4}, Michael J Joyner³, David J Sullivan⁵, Andrew Pekosz⁵, Fabrizio Maggi⁶, Arturo Casadevall⁵

Affiliations

¹ North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
² Division of Hematology and Transfusion Medicine, Mantua Hospital, Mantua, Italy.
³ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Department of Kinesiology and Community Health, University of Illinois Urbana-Champaign, Urbana, Illinois, USA.
⁵ Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
⁶ National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy.

PMID: 38635404
DOI: 10.1002/rmv.2533

Abstract

Influenzavirus is among the most relevant candidates for a next pandemic. We review here the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly reviewing the other existing antiviral options, we discuss in detail the evidences supporting the efficacy of passive immunotherapies against influenzavirus, with a focus on convalescent plasma.

Keywords: H1N1pdm09; H5N1; H7N9; bird fu; convalescent plasma; influenza virus; pandemic influenza; swine flu.

Publication types

Review

MeSH terms

Humans
Immunotherapy
Influenza A Virus, H7N9 Subtype*
Influenza, Human* / epidemiology
Influenza, Human* / prevention & control
Pandemics